Attached files
file | filename |
---|---|
10-K - 10-K - ENDOCYTE INC | ecyt-20171231x10k.htm |
EX-32.1 - EX-32.1 - ENDOCYTE INC | ecyt-20171231ex32152315f.htm |
EX-31.2 - EX-31.2 - ENDOCYTE INC | ecyt-20171231ex312ae6824.htm |
EX-31.1 - EX-31.1 - ENDOCYTE INC | ecyt-20171231ex311ab26fb.htm |
EX-23.1 - EX-23.1 - ENDOCYTE INC | ecyt-20171231ex231f0460a.htm |
EX-10.22 - EX-10.22 - ENDOCYTE INC | ecyt-20171231ex102216d99.htm |
EX-10.19 - EX-10.19 - ENDOCYTE INC | ecyt-20171231ex101946a4d.htm |
EX-10.16 - EX-10.16 - ENDOCYTE INC | ecyt-20171231ex10169a090.htm |
EX-10.13 - EX-10.13 - ENDOCYTE INC | ecyt-20171231ex10130116e.htm |
Exhibit 10.26
ENDOCYTE, INC.
SCHEDULE OF TERMS FOR
CHANGE IN CONTROL AND SEVERANCE AGREEMENTS
WITH EXECUTIVE OFFICERS
February 2018
Termination without Cause or Resignation for Good Reason, prior to a Change in Control or after 12 months following a Change in Control |
Termination without Cause or Resignation for Good Reason, within 12 months following a Change in Control |
|||||||
Name of Executive Officer |
Date of Agreement |
Severance Payment – Percentage of Base Salary |
140% COBRA Continuation |
Accelerated vesting for equity awards that would have vested over the following |
Severance Payment – Percentage of Base Salary |
Severance Payment – Percentage of Target Bonus |
140% COBRA Continuation |
Percentage of unvested equity awards that will immediately vest |
Michael A. Sherman |
6/17/16 |
100% |
12 months |
12 months |
200% |
200% |
24 months |
100% |
Michael A. Andriole |
2/20/17 |
75% |
9 months |
9 months |
150% |
150% |
18 months |
100% |
Alison A. Armour |
8/10/15 |
75% |
9 months |
9 months |
150% |
150% |
18 months |
100% |
Beth A. Taylor |
5/15/15 |
75% |
9 months |
9 months |
100% |
100% |
12 months |
100% |
Erik Chelius |
2/21/18 |
75% |
9 months |
9 months |
100% |
100% |
12 months |
100% |
Christopher P. Leamon |
5/15/15 |
75% |
9 months |
9 months |
150% |
150% |
18 months |
100% |
Katherine K. Parker |
5/15/15 |
75% |
9 months |
9 months |
100% |
100% |
12 months |
100% |